Vertex Pharmaceuticals Inc

VRTX

NASDAQ. Currency in USD

291.59 -13.21 ( -4.33% )

Real time prices: December 19

Market Cap.
74.85B
Beta (5Y monthly)
0.43
Price/Earnings
22.16
EPS (TTM)
14.50
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
1.65M
1y Target Est.
324.62
Day's Range
289.48
-
302.59
52 Week's Range
225.28
-
324.75

Historical Summary

Performance
EPS growth
Share Buybacks

About Vertex Pharmaceuticals Inc

Sector
Healthcare
Industry
Biotechnology
Website
https://www.vrtx.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
254.25M
Employees
3900
Address
50 Northern Avenue, Boston, MA, United States, 02210
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Latest news

Benzinga's Top Ratings Upgrades, Downgrades For December 19, 2022
Benzinga's Top Ratings Upgrades, Downgrades For December 19, 2022

Upgrades For NRG Energy Inc (NYSE:NRG), B of A Securities upgraded the previous rating of...
By Benzinga - 6 weeks ago

The Zacks Analyst Blog Highlights Merck, Vertex Pharmaceuticals, Immunocore Holdings and Immunovant
The Zacks Analyst Blog Highlights Merck, Vertex Pharmaceuticals, Immunocore Holdings and Immunovant

Merck, Vertex Pharmaceuticals, Immunocore Holdings and Immunovant are part of the Zacks top Analyst Blog.
By Zacks Investment Research - 6 weeks ago

Where Will Vertex Pharmaceuticals Be in 10 Years?
Where Will Vertex Pharmaceuticals Be in 10 Years?

Expect a bigger, more diversified, and more entrenched entity to emerge over the coming years.
By The Motley Fool - 6 weeks ago

Buying These Unstoppable Stocks Before 2023 Could Be a Genius Move
Buying These Unstoppable Stocks Before 2023 Could Be a Genius Move

These stocks have climbed by double digits this year.
By The Motley Fool - 6 weeks ago

Better Bear Market Buy: Vertex Pharmaceuticals vs. Biogen Stock
Better Bear Market Buy: Vertex Pharmaceuticals vs. Biogen Stock

Both stocks are heading for double-digit gains this year.
By The Motley Fool - 6 weeks ago

My 3 Best Stocks of 2022 -- and Why I Think They'll Win Again in 2023
My 3 Best Stocks of 2022 -- and Why I Think They'll Win Again in 2023

The momentum for these high-flying stocks should continue in the new year.
By The Motley Fool - 6 weeks ago

Should You Buy Stocks If a Recession Is Coming in 2023? Here's What History Shows.
Should You Buy Stocks If a Recession Is Coming in 2023? Here's What History Shows.

Stocks usually go down during recessions, but long-term investors can still come out on top.
By The Motley Fool - 6 weeks ago

Which Is the Better Buy: Vertex or Invitae?
Which Is the Better Buy: Vertex or Invitae?

Is Vertex worth its lofty valuation compared to Invitae?
By The Motley Fool - 7 weeks ago